Tirzepatide side effects and diarrhoea: what the evidence says

What the SURMOUNT trial data actually showed about diarrhoea

The SURMOUNT-1 trial, which randomised 2,539 adults with obesity over 72 weeks, reported diarrhoea as one of tirzepatide's most frequent adverse events. At the 15 mg maintenance dose, roughly 23% of participants experienced it, compared with around 10% on placebo. The pattern across all doses was consistent: events clustered in the early weeks and after each upward titration step, then became less frequent as participants settled at a steady dose. The SURMOUNT-1 paper in the New England Journal of Medicine classified the overwhelming majority of these events as mild or moderate. Severe diarrhoea leading to discontinuation was uncommon. That context matters. A side effect appearing in trial data does not mean every person will experience it, but it does mean you should know what to look for and when to act.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is part of why GI effects appear at all. Slowing gastric emptying is central to how the medicine reduces appetite, and that same slowing can disrupt the gut's normal rhythm, especially early on. More on the underlying mechanism is covered on our page about why tirzepatide causes diarrhoea.

The practical pattern: when diarrhoea tends to strike and what usually helps

For most people, the timing follows a predictable arc. The first injection (at the 2.5 mg starting dose, which exists primarily to let your system adjust rather than to drive weight loss) often brings the most noticeable GI disruption. A similar pattern can repeat with each dose increase. Between increases, things generally settle. That is reassuring, because it means the discomfort is not simply a permanent feature of life on tirzepatide.

Practical steps that consistently come up in clinical guidance: eating smaller portions, avoiding very fatty or fried food around injection day, keeping fluids up, and not rushing meals. Some people find keeping the pen in the fridge door acts as a useful reminder to think about the evening's food choices, since injection day and the day after are when symptoms tend to peak. Alcohol can worsen GI effects and is worth moderating. These are general measures, not a substitute for your prescriber's advice, if diarrhoea is severe or prolonged, speak with a clinician rather than adjusting anything yourself. Our full tirzepatide side effects page covers the wider GI profile in more detail.

When diarrhoea signals something that needs urgent attention

Ordinary loose stools in the early weeks are one thing. There are, however, symptoms that should prompt you to seek medical help promptly rather than waiting to see whether they resolve.

Severe, persistent stomach pain (particularly pain that radiates towards the back, with or without vomiting) is not typical diarrhoea and may indicate pancreatitis. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious known risk with GLP-1 medicines including tirzepatide. Seek urgent medical attention if you experience this symptom pattern; do not wait.

Beyond pancreatitis, significant diarrhoea combined with vomiting can lead to dehydration quickly. Signs to watch for include very dark urine, dizziness on standing, and a dry mouth that does not resolve with drinking. If you cannot keep fluids down, that is a reason to contact NHS 111 or your GP on the same day. Suspected side effects can be reported directly to the MHRA via the Yellow Card scheme, this is open to patients as well as healthcare professionals, and reports genuinely inform ongoing safety monitoring.

What to tell your prescriber, and how the consultation at nume works

If you are considering tirzepatide, GI side effects including diarrhoea will be part of what a prescriber reviews with you. Certain conditions (including active or recurrent GI disease) affect whether treatment is appropriate, and a thorough consultation is where that gets established. At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber; the process is described on our about us page. There are no algorithms making prescribing decisions.

If you are already on treatment elsewhere and finding diarrhoea difficult to manage, it is worth raising it at your next clinical review rather than stopping the pen abruptly. Stopping GLP-1 treatment abruptly without prescriber guidance is not recommended. For those thinking about starting, our free consultation is the place to discuss your history and any concerns, including whether tirzepatide is likely to cause diarrhoea for you specifically given your medical history. You can also browse our Mounjaro side effects overview or, if you have specific questions about diarrhoea and Mounjaro by brand name, our dedicated Mounjaro diarrhoea page covers that ground. We also have a detailed guide on managing diarrhoea while taking tirzepatide, which covers practical strategies and when to seek further help.